

This document is intended to provide health care providers with approaches for individuals who have received COVID-19 vaccination outside of Canada. The WHO list of EUA qualified COVID-19 vaccines will be updated over time as additional COVID-19 vaccines receive emergency use listing, and as such, this document will be updated accordingly. More information on COVID-19 vaccines listed for emergency use can be found on the [WHO website](#), under the tab “Status of COVID-19 vaccines within WHO EUL/PQ evaluation process.”

| Manufacturer | Name of Vaccine | Type of vaccine | WHO EUA qualified | Approved schedule ^{1, 2} | Second dose options for completion of series in BC ³ |
|--|--|-------------------------------|-------------------|-----------------------------------|---|
| Pfizer-BioNTech | BNT162b2 / COMIRNATY / Tozinameran (INN) | mRNA | ✓ | Two doses, 21-28 days apart | - Moderna - Pfizer-BioNTech |
| Moderna | mRNA-1273 | mRNA | ✓ | Two doses, 28 days apart | - Moderna - Pfizer-BioNTech |
| AstraZeneca | AZD1222 Vaxzevria | Adenovirus (CHAdOx1) vector | ✓ | Two doses, 4-12 weeks apart | - Moderna - Pfizer-BioNTech |
| Serum Institute of India | COVISHIELD | Adenovirus (CHAdOx1) vector | ✓ | Two doses, 4-12 weeks apart | - Moderna - Pfizer-BioNTech |
| Janssen (Johnson & Johnson) | Ad26.COV2.5 | Adenovirus type 26 vector | ✓ | One dose | N/A - one dose series |
| SinoPharm / Beijing Institute of Biological Products (BIBP) ⁴ | Covilo / BBIBP-CorV | Whole inactivated Coronavirus | ✓ | Two doses, 21-28 days apart | - Moderna - Pfizer-BioNTech |
| Sinovac | CoronaVac | Whole inactivated Coronavirus | ✓ | Two doses, 14-28 days apart | - Moderna - Pfizer-BioNTech |
| Bharat Biotech, India | COVAXIN | Whole inactivated Coronavirus | ✓ | Two doses, 28 days apart | - Moderna - Pfizer-BioNTech |
| Novavax | NVX-CoV2373 / Nuvaxovid | Protein subunit | ✓ | Two doses, 21-28 days apart | - Moderna - Pfizer-BioNTech - Novavax |
| Serum Institute of India | NVX-CoV2373 / Covovax | Protein subunit | ✓ | Two doses, 21-28 days apart | - Moderna - Pfizer-BioNTech |
| CanSinoBio | Ad5-nCoV | Adenovirus Type 5 vector | ✓ | One dose | N/A - one dose series |
| Russian Direct Investment Fund | Sputnik V | Human adenovirus vector | pending | | |
| SinoPharm / Wuhan Institute of Biological Products (WIBP) | Inactivated SARS-CoV-2 Vaccine (Vero Cell) | Whole inactivated Coronavirus | pending | | |
| Sanofi | CoV2 preS dTM-AS03 vaccine | Recombinant, adjuvanted | pending | | |

| Manufacturer | Name of Vaccine | Type of vaccine | WHO EUA qualified | Approved schedule ^{1, 2} | Second dose options for completion of series in BC ³ |
|---------------------------|---------------------------------------|-------------------------------|-------------------|-----------------------------------|---|
| Clover Biopharmaceuticals | SCB-2019 | Recombinant protein subunit | pending | | |
| Zhifei Longcom (China) | Recombinant Novel Coronavirus Vaccine | Recombinant protein subunit | pending | | |
| Shifa Pharmed-Barkat | CovIran [®] vaccine | Whole inactivated Coronavirus | pending | | |
| CIGB | Abdala | Protein subunit | pending | | |
| SK Bioscience | Nuvaxovid prefilled syringe | Protein subunit | pending | | |

¹ Individuals who have received a complete series with a vaccine that is WHO EUA qualified are considered fully vaccinated within the primary series. However, one additional dose of a COVID-19 mRNA vaccine should be provided for individuals upon request if they have been vaccinated with 2 doses of a WHO-approved vaccine series that is not authorized in Canada. The minimum interval between the preceding dose and the additional dose is 4 weeks. If the additional dose is provided at least 8 weeks after the preceding dose, this will be considered as a valid booster dose. Note: If Moderna vaccine is provided, the age-appropriate primary series dosage should be administered. If they have already received three or more doses of a WHO-approved/non-Health Canada COVID-19 vaccine, they do not need an additional dose unless they are due for their booster dose. Offer booster dose(s) as appropriate.

² Individuals who have received a series with a vaccine that is not WHO EUA qualified should be offered a full COVID-19 vaccine series using a vaccine available in BC. There is no minimum interval required when restarting the series following receipt of a non-WHO approved vaccine.

³ Individuals who have received a first dose of a COVID-19 vaccine overseas that is also available in BC may receive the same vaccine for their second dose if readily available, however an mRNA COVID-19 product is preferred. Novavax COVID-19 vaccine may be offered to individuals for whom COVID-19 mRNA vaccines are contraindicated or have been refused. Novavax COVID-19 vaccine is interchangeable with mRNA and viral vector COVID-19 vaccines within the primary series and/or booster dose. An 8 week interval between doses is recommended. A minimum interval of 4 weeks is acceptable, if required.

⁴ This includes BIBP products from Chengdu Institute of Biological Products (CDIBP); Lanzhou Institute of Biological Products (LIBP) and Changchun Institute of Biological Products (CCIBP).